Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1782525 | 0.69 | ALDH1A1 (0.45) | ALDH1A1KDM4EGAAKMT2ALMNA | |
| SCHEMBL7905948 | 0.68 | KDM4E (0.35) | ALDH1A1KDM4EGAAKMT2AHPGD | |
| SCHEMBL31201062 | 0.67 | ALDH1A1 (0.42) | ALDH1A1KDM4EGAAKMT2ALMNA | |
| SCHEMBL17895476 | 0.67 | ALDH1A1 (0.42) | ALDH1A1KDM4EGAAKMT2ALMNA | |
| SCHEMBL17476686 | 0.66 | KDM4E (0.48) | ALDH1A1KDM4EGAAKMT2ALMNA | |
| SCHEMBL6558303 | 0.66 | ALDH1A1 (0.53) | ALDH1A1KDM4EGAAKMT2ALMNA | |
| SCHEMBL12402334 | 0.65 | ALDH1A1 (0.57) | ALDH1A1KDM4EGAAKMT2ALMNA | |
| SCHEMBL10136903 | 0.65 | ALDH1A1 (0.57) | ALDH1A1KDM4EGAAKMT2ALMNA | |
| SCHEMBL12402363 | 0.63 | ALDH1A1 (0.41) | ALDH1A1KDM4EGAAKMT2ALMNA | |
| SCHEMBL21721831 | 0.62 | ALDH1A1 (0.53) | ALDH1A1KDM4EGAAKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | claimed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | claimed |
| EP-1970377-A1 | LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2008-09-17 | — | — | EP | claimed |
| US-20240270740-A1 | INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. | 2024-08-15 | — | — | US | disclosed |
| EP-2902026-A1 | THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF METABOLIC INFLAMMATION MEDIATED DISEASE | Metabolic Solutions Development Company LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2486926-A1 | Thiazolidinedione Analogues | Metabolic Solutions Development Company LLC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-2001468-A2 | THIAZOLIDINEDIONE ANALOGUES | Metabolic Solutions Development Company (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1970377-A1 | LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007109024-A2 | THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF METABOLIC INFLAMMATION MEDIATED DISEASE | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270740-A1 | INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | CGAS, GMPS, PRKG1 | ALDH1A1 1281/4885KDM4E 3763/4885GAA 59/4885 |
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | ALDH1A1 2976/4885KDM4E 3077/4885GAA 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.